Cardiac Disease, Hypoxic-Ischemic Encephalopathy, Kidney Diseases, Metabolic Disease, Pulmonary Disease, Sepsis, Twin to Twin Transfusion Syndrome
Conditions
Brief summary
Historically, CKRT and hemodialysis were performed in small infants and newborns with devices developed for adults with high rates of complications and mortality. We aim to retrospectively report the first multicenter French experience of CARPEDIEM® use and evaluate the efficacy, feasibility, outcomes, and technical considerations of this new device in a population of neonates and small infant. Compared to adult's device continuous renal replacement therapy with an adapted machine allowed successful blood purification without severe complications even in low birth weight neonates.
Interventions
DEVICECARPEDIEN
Continuous renal replacement therapy
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 3 Years
Healthy volunteers
No
Inclusion criteria
* Children and neonates including premature and low birth weight neonates * Have a diagnosis of acute kidney injury, end stage renal disease, metabolic disease, electrolyte abnormality * Require renal replacement therapy
Exclusion criteria
-Renal replacement therapy with another device than Carpediem machine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival | 3 years |
| Serum creatinine | 3 years |
| Serum potassium | 3 years |
| Blood urea nitrogen | 3 years |
| Ammonia levels | 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood flow | 3 years | The range of blood flow in ml/kg/min ( compared to the recommend blood flow of 3-10 ml/kg/min). |
| Anticoagulation | 3 years | The dose of continuous heparin anticoagulation in UI/Kg/h to prevent circuit clotting. |
| Number of sessions | 3 years | — |
| Vascular access | 3 years | The localization of a vascular access ( intern jugular, subclavian, umbilical or femoral). |
| CKRT modality | 3 years | — |
| Clotting circuit and other dysfunction circuit | 3 years | * Dysfunction circuit included cathether dysfunction, pressure dysfucntion and failure restitution * Complications of an extra corporel therapy including hypotension, thrombocytopenia and clotting circuit. |
| Time of treatments | 3 years | — |
| Priming circuit | 3 years | The priming circuit ( normal salin, albumin, Isofundin or packed red blood cells). |
| Size of the circuit | 3 years | — |
| Death | 3 years | — |
| Ultrafiltration flow | 3 years | the substitution range with the effluent volume in ml/kg/h ( compared to the KDIGO recommend of 25-35 ml/kg/h) |
Countries
France
Outcome results
None listed